
Mineralys Therapeutics, Inc.: updates and filings
Price
$13.66
November 20, 2026Market cap $1.2B
What Ploutos Investor adds for Mineralys Therapeutics
Part of Ploutos Investor, €9.99 a month
- The full history: 4 fiscal years, from 2022
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
What comes next, and what happened
Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.
November 2026
October 2026
August 2026
June 2026
May 2026
Its SEC filings
What it has filed lately, newest first, linked to the document itself.
- Nov 4, 2026Quarterly reportfor the period to Sep 30, 2026Form10-Q
- Nov 4, 2026Results of operations, officer or director changeForm8-K
- Oct 29, 2026Material agreement entered, material agreement endedForm8-K
- Oct 19, 2026Officer or director changeForm8-K
- Aug 11, 2026Quarterly reportfor the period to Jun 30, 2026Form10-Q
- Aug 11, 2026Results of operations, officer or director changeForm8-K
- Aug 6, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Jul 14, 2026Filing (amendment)Form144/A
- Jun 3, 2026Other material eventsForm8-K
- Jun 3, 2026Material agreement entered, new material financial obligationForm8-K
- May 22, 2026Shareholder voteForm8-K
- May 6, 2026Quarterly reportfor the period to Mar 31, 2026Form10-Q
- May 6, 2026Results of operationsForm8-K
- Apr 10, 2026Annual report to shareholdersfor the period to Dec 31, 2025FormARS
- Apr 8, 2026Additional annual meeting materialFormDEFA14A
- Apr 8, 2026Annual meeting proxy statementFormDEF 14A
- Mar 12, 2026Annual reportfor the period to Dec 31, 2025Form10-K
- Mar 12, 2026Results of operationsForm8-K
- Mar 9, 2026Regulation FD disclosure, other material eventsForm8-K
- Feb 13, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Feb 13, 2026Shares registered for employeesFormS-8
- Feb 5, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Jan 21, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Jan 6, 2026Regulation FD disclosure, other material eventsForm8-K
- Nov 10, 2025Shelf registration for future offeringsFormS-3ASR
| Filed | Form | What it is | Filing |
|---|---|---|---|
| Nov 4, 2026 | 10-Q | Quarterly reportfor the period to Sep 30, 2026 | Document |
| Nov 4, 2026 | 8-K | Results of operations, officer or director change | Document |
| Oct 29, 2026 | 8-K | Material agreement entered, material agreement ended | Document |
| Oct 19, 2026 | 8-K | Officer or director change | Document |
| Aug 11, 2026 | 10-Q | Quarterly reportfor the period to Jun 30, 2026 | Document |
| Aug 11, 2026 | 8-K | Results of operations, officer or director change | Document |
| Aug 6, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Jul 14, 2026 | 144/A | Filing (amendment) | Document |
| Jun 3, 2026 | 8-K | Other material events | Document |
| Jun 3, 2026 | 8-K | Material agreement entered, new material financial obligation | Document |
| May 22, 2026 | 8-K | Shareholder vote | Document |
| May 6, 2026 | 10-Q | Quarterly reportfor the period to Mar 31, 2026 | Document |
| May 6, 2026 | 8-K | Results of operations | Document |
| Apr 10, 2026 | ARS | Annual report to shareholdersfor the period to Dec 31, 2025 | Document |
| Apr 8, 2026 | DEFA14A | Additional annual meeting material | Document |
| Apr 8, 2026 | DEF 14A | Annual meeting proxy statement | Document |
| Mar 12, 2026 | 10-K | Annual reportfor the period to Dec 31, 2025 | Document |
| Mar 12, 2026 | 8-K | Results of operations | Document |
| Mar 9, 2026 | 8-K | Regulation FD disclosure, other material events | Document |
| Feb 13, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Feb 13, 2026 | S-8 | Shares registered for employees | Document |
| Feb 5, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Jan 21, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Jan 6, 2026 | 8-K | Regulation FD disclosure, other material events | Document |
| Nov 10, 2025 | S-3ASR | Shelf registration for future offerings | Document |
From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Jun 13, 2022.
The full analysis
What do Mineralys Therapeutics's filings show?
The filings are where every one of Mineralys Therapeutics's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.